Replies to post #242448 on Amarin Corp Plc (AMRN)

[Crikker]

Not sure why the $1 billion excitement with BP marketing. With AMRN projecting roughly $700 million this year, we should surpass the $1 billion in 2021. That is with SP (small pharma) marketing and no Europe, rest of world, etc...

2021 would be the same stage as Ozempic 2019 for Vascepa after the Reduce It label approval..

[sts66]

I thought the same initially when I read that - but don't forget it includes the word "global" - much easier to hit $1B in sales when you're able to sell in the EU. Assuming V follows a similar track, and it should do so easily given that we have zero competition, whereas the diabetes market is filled with them, our "launch" is 2020, and > $1B sales should be hit in 2021 (US only). Medicare Part D plans moving V up a tier to preferred brand will provide a major boost in 2021 - I'm hopeful it might happen in H2/2020 but not counting on it - since I've been on Medicare (2010) none of my plans have changed coverage levels of a drug I take during a plan year, they only updated formularies for the next plan year prior to the start of open season.